NCT03610061 2024-04-12
RaDD
Austin Health
Phase 1 Completed
Clinical Trials
6 trialsNCT03310619 2024-04-04
PLATFORM
Celgene
Phase 1/2 Completed
NCT02793466 2023-09-22
Durvalumab in Pediatric and Adolescent Patients
Children's Hospital Los Angeles
Phase 1 Completed
NCT02643303 2022-12-02
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
Ludwig Institute for Cancer Research
Phase 1/2 Completed
NCT02401048 2019-06-27
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Pharmacyclics LLC.
Phase 1/2 Completed
NCT02549651 2019-02-27
MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)
MedImmune LLC
Phase 1 Completed